ERYP - Erytech jumps 32% after securing U.S. patent for methioninase & asparaginase in solid tumors

Erytech Pharma (NASDAQ:ERYP) announces the granting of U.S. patent 11,141,468, covering methods of treating solid tumors by administering methioninase and asparaginase. Shares surge 31.9% premarket at $3.14. The patent, entitled “Method of treating a mammal, including human, against cancer using methionine and asparagine depletion”, emphasizes ERYTECH’s continuing innovation in the delivery of safe and effective enzymatic activity for depriving tumors of essential nutrients. In total, Erytech’s IP portfolio now includes 16 global patent families with over 310 patents and 45 applications. These patent families protect the company's red blood cell encapsulation technology (ERYCAPS), its therapeutics for Oncology, Rare Metabolic Diseases, and Immune Modulation, as well as its methods for producing Cargo-Loaded Red Cell Extracellular Vesicles.

For further details see:

Erytech jumps 32% after securing U.S. patent for methioninase & asparaginase in solid tumors